Transarterial Chemoembolization for HCC with Drug-Eluting Microspheres by Maurizio Grosso et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
15 
Transarterial Chemoembolization for  
HCC with Drug-Eluting Microspheres 
Maurizio Grosso, Fulvio Pedrazzini, Alberto Balderi,  
Alberto Antonietti, Enrico Peano, Luigi Ferro and Davide Sortino 
A. O. S. Croce e Carle, Cuneo 
Italy 
1. Introduction 
HCC is the 5th most common cancer worldwide and the 3rd cause of cancer related deaths. 
Transarterial chemoembolization (TACE) is the mainstay therapy for intermediate non-
resectable HCC, according to the BCLC Staging system. (Bruix & Sherman, 2011). 
TACE significantly improves the overall rate of survival after 2 years compared with 
conservative treatment, but there is no evidence that TACE is more effective than 
transarterial embolization (TAE). However in more selected patients the 1 year survival rate  
 
Fig. 1. TACE with Lipiodol. 
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is 82% after TACE, 75% after TAE and 63% after conservative treatment, while it is 63%, 50% 
and 27% respectively at 2 years (Llovet et al, 2002). Even if it is well known that Lipiodol 
stays for a prolongued period in the tumor after TACE, pharmacokinetic studies about 
traditional TACE with Lipiodol (Figure 1) and drug demonstrate that plasma levels of 
adriamycin are identical with intraarterial administration with or without Lipiodol. 
With the aim of two different kind of drug-loaded carriers have been increasing the local 
concentration of the drugs and reducing systemic side effects introduced for transarterial 
treatment of HCC: HepaSphere™ Microspheres (BioSphere Medical, France) and DC Bead™ 
Microspheres (Biocompatibles, UK). 
The aim of this study is to analyze the data recently published regarding DC Bead™ 
Microspheres and to present our experience with chemoembolization with HepaSphere™ 
Microspheres. 
2. Conventional chemoembolization 
Transarterial chemoembolization consists of the administration of chemotherapeutic drugs 
mixed with an embolizing material. It combines therapeutic effects of peripheral arterial 
occlusion with the local administration of chemoterapeutic agents. The target of arterial 
chemoembolization through the hepatic artery are to increase the local concentration of 
chemotherapeutic drugs in the tumor and reduce systemic side effects. The arterial system, 
mainly supplied vascularization of HCC unlike cirrhotic tissue,  where vascularization is 
mainly supplied by the portal vein system. TACE can involve the whole hepatic 
parenchyma (embolization of the common hepatic artery or left/right hepatic artery) or can 
be selective (embolization of segmental/subsegmental hepatic artery) with better tumoral 
response and lower hepatic damage.  
There is a great variability in the nature and description of transarterial techniques. There 
are at least four different kind of locoregional treatment: TACE (transarterial 
chemoembolization); TAE (transarterial embolization); TOCE (transarterial oily 
chemoembolization) and TAC (transarterial chemotherapy). TACE has been already 
described. TAE refers only to the last process, which may be preceded by the administration 
of Lipiodol (Lp-TAE), without using any chemotherapeutic  agents. TOCE consists in the 
arterial administration of a mixture of anticancer drugs and Lipiodol without  
embolizzation. TAC is  the  locoregional infusion of chemotherapeutic agents   through a 
catheter placed into the hepatic artery. (Marelli et al, 2007) 
There is not yet a wide consensus about the characteristics of the patients suitable to undergo 
TACE. Selection criteria could be based on any combination of tumor dimension (tumor size, 
amount of liver replacement by tumor, serum -phafetoprotein,portal vein thrombosis or 
obstruction), severity of   liver disease (Child-Pugh score, serum bilirubin, serum albumin and 
ascites), health status (Karnofsky score, Performance Status test, and constitutional syndrome), 
and response to treatment. All these criteria have been found to be predictors of survival in 
patients undergoing TACE. The majority of studies included patients defined as having 
‘‘unresectable HCC,’’ that is HCC diagnosed according to the 2000 Barcelona EASL criteria, 
not suitable for curative treatments according to BCLC staging classification and treatment 
schedule. Exclusion criteria in different trials were: advanced liver disease (Child-Pugh C), 
active gastrointestinal bleeding, encephalopathy, refractory ascites, presence of vascular 
www.intechopen.com
 Transarterial Chemoembolization for HCC with Drug-Eluting Microspheres 
 
267 
invasion or total portal vein occlusion due to liver tumor, extrahepatic metastases,  any 
contraindication to an arterial procedure (impaired clotting tests and renal failure), WHO 
performance stage 3 or 4, and end-stage tumoral disease (Okuda III). (Marelli et al, 2007) 
The indications have beeen explained by Barcelona Clinic Liver Cancer (BCLC) tumor 
staging; it combines the stage of liver disease, tumor stage, clinical performance, and 
treatment options and is certified by the European Association for the Study of Liver 
Disease(EASL) and the American Association for the Study of Liver Disease (AASLD). 
Actually, TACE is indicated in intermediate state (Bruix & Sherman, 2011). 
Therefore absolute contraindications to TACE   are Child C or Okuda III, tumor resecability 
or suitable for percuteneous ablations , sepsis, hepatic encephalopathy, uncorrectable 
contrast allergy or coagulation disorders, leucopenia ( WBC<1000/µl), cardiac or renal 
insufficiency (serum creatinine>2 mg/dl) and complete portal vein thrombosis. 
Relative contraindications are: serum bilirubin >3 mg/dl,  LDH (lactate dehydrogenase) >425 
U/l, AST (aspartate aminotransferase) >5X the upper limit of normal, extrahepatic metastases, 
tumor burden involving >50% of the liver, performance status (PS) >2, renal or cardiac 
insufficiency, recent variceal bleeding, or significant thrombocytopenia, intractable fav 
(arteriovenous fistula), ascites, surgical portocaval anastomosis, tumor invasion to inferior 
vena cava and right atrium, severe portal vein thrombosis. (Liapi & Geschwind, 2011) 
Lipiodol (ethiodized oil) is an oily contrast medium which persists more selectively in tumor 
nodules for a few weeks or months when injected into the hepatic artery, due to the arterial 
hypervascularization and absence of Kupffer cells inside the tumor tissue, but it may also 
persist to a lesser extent in non-neoplastic nodules. Even if some investigators still believe in 
the embolic effect of lipiodol, nowadays it cannot be considered as an embolic agent since it 
does not result in arterial occlusion. It is used only as a vehicle to carry and localize 
chemotherapeutic agents inside the tumor. However, the major problem is how to combine 
anticancer drugs, which are water-based preparations, and lipiodol, which is an oil-based 
agent, in a stable formulation able to deliver drugs slowly over time. (Marelli et al, 2007) 
The most common sole-agent anticancer drug used in literature is doxorubicin (36%), 
followed by cisplatin (31%), epi/doxorubicin (12%), mitoxantrone (8%), mitomycin C (8%), 
and SMANCS (5%). SMANCS is a chemical conjugate of a synthetic copolymer of styrene 
maleic acid (SMA) .  
To date there is no evidence of superior efficacy of any chemotherapeutic agent alone or of 
monotherapy versus combination therapy. Anticancer drugs dosage was variable and not 
reported iaccording to standards: some studies used a fixed dose, some based the dosage on 
body surface area and others on patient weight, tumor size or bilirubin level. (Marelli et al, 2007) 
The embolization endpoint is to achieve complete occlusion of the neo-vascularity, avoiding  
complete stasis in the afferent artery, which would lead to endothelial damage and 
subsequent thrombosis and would preclude future treatments. The embolized vessels are 
generally segmentary and subsegmentary branches. 
Operative indications are: 
1. Choose a delivery microcatheter based on the size of the target vessel. 
2. Position the catheter tip as close as possible to the treatment site to avoid inadvertent 
occlusions of normal vessels and damage of “non-target” hepatic tissue. Large catheter 
causes “stop flow” with less selectivity and less accuracy in target embolization. 
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Undesirable reflux or passage of chemoembolic agent into normal arteries (adjacent to the 
target lesion or through the lesion into other arteries or arterial beds) can occur during 
embolization , with consequent non-target ischaemia (splenic, gastroduodenal, left, or right 
arteries embolization, etc.). 
Post embolic syndrome (fever >38° C, nausea, vomiting, abdominal pain) frequently occurs after 
conventional TACE (90%), probably caused by inflammatory response  and tissue ischemia.  
Liver ascess and acute liver failure occur in 2%, while ascites, transient abdominal pain, pleuric 
effusion, haemoperitoneum, splenic embolization, cardiac failure, thrombosis of hepatic artery, 
gastric ulcer bleeding, esophageal variceal bleeding,  between  8 to 1% in the differents series. 
The results of TACE in different series are  reported in table 1-2-3. In randomized studies 
TACE improves survival in comparison with conservative treatments. Drug-eluting 
Microspheres increase the percentage of tumor tissue necrosis against the traditional TACE. 
 
Authors 100% 99-88% 79-50% < 50% 
Hashimoto T 
Nakamura H 
Hori S 
Tomoda K 
 
29% 
 
43% 
 
12% 
 
 
16% 
 
Morino M 
Grosso M 
De Giuli M 
Bismuth H 
 
 
27%
 
 
30%
 
 
19%
 
 
 
23% 
Table 1. Necrosis grading post-TACE 
 
Authors N. Pts Survival
1 year             3 year           5 year 
Atanaka 
Savastano 
Shijo 
Ukida 
Grosso 
2159
57 
110 
1075 
340
65%
75% 
79% 
61% 
59%
36%
9 % 
38% 
15% 
27%
18% 
- 
14% 
- 
17% 
Table 2. TACE results. 
 
Authors N. Pts Survival
1 year             3 year           5 year 
Yamada 
Bronowiki 
973
127 
51%
65% 
12%
 
27%
6 % 
- 
 
Table 3. Segmental TACE results. 
2.1 TACE with DcBead™ Microspheres 
DC Bead™ Microspheres are Polyvinyl Alcohol polymer hydrogel N-Fil sulfonic acid 
Microspheres. They can be loaded with doxorubicin to provide accurate dosage of the drug 
and be suitable for superselective TACE. DC Bead™ primary embolic characteristics allow 
accurate, targeted delivery. They are available in a range of sizes associated to different colours 
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(yellow: 100-300 µm; blue: 300-500 µm; red: 500-700 µm; green: 700-900 µm), while volume of 
Beads is 2 ml. The 100-300 µm microspheres are generally used in standard TACE, while 300-
500 µm or 500-700 µm are used only in huge lesions or presence of arterial-portal fystulas 
Choosing the appropriate size of  microspheres best matches the pathology (i.e. tumour 
lesion/vessel size) provides the expected clinical outcome. Systemic plasma level of 
doxorubicin is 30 times lower in patients treated with DC Bead™ vs those treated with 
conventional TACE. DC Bead™ are hydrated and interaction of doxorubicin with SO3 groups 
displaces water from the hydration shells DC Bead™ drug delivery properties are explained as 
it follows: loads and elutes drugs relevant to clinical use; uniform distribution of drug 
throughout the loaded beads; consistent local delivery to the tumour, over an extended period. 
With DC Bead™ drug elution is dependent on ion exchange and is controlled and sustained – 
unlike the rapid separation of the drug from Lipiodol. DC Bead™ should enable delivery of 
drug to the tumour site over an extended period while minimising systemic release of 
doxorubicin and reducing the side effects associated with conventional TACE. 
2.1.1 TACE with DcBead™ Microspheres: Preparation 
DC Bead™ Microspheres can be loaded with Doxorubicin-HCl (up to 37.5 mg/mL; 
maximum dose/patient of 150 mg).  
1. Reconstitute each 50mg doxorubicin vial with 2ml of sterile water for injection. Mix well 
to obtain a clear solution. 
2. Remove as much saline as possible from DC Bead™ vial(s) using a syringe with a small 
gauge needle. Pierce bung with a second needle to eliminate vacuum. If a filter needle is 
not available, place flattened tip of needle against side of vial to prevent beads being 
drawn up the needle. 
3. Using a syringe and needle add the reconstituted doxorubicin solution directly to the 
vial(s) of DC Bead™. 
4. Agitate the DC Bead™/doxorubicin solution gently to encourage mixing then allow to 
stand until the beads are red and the solution is almost colourless. 
5. DC Bead™ loading time is dependent on bead size. 
6. Transfer the loaded beads into a 10ml syringe. Add an equal volume of non-ionic 
contrast media and mix gently (a 3-way connector and second syringe can be used). 
 
Fig. 2. TACE with DC Bead™ Microspheres. 
Figures 2-3-4 demonstrate a case of HCC we treated with TACE with DC Bead™ 
Microspheres and the CT-follow-up at 1 and 6 months. 
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Fig. 3. 1-months CT follow-up of TACE with DC Bead™ Microspheres: complete necrosis of 
treated lesions. 
 
Fig. 4. 6-months CT follow-up of TACE with DC Bead™ Microspheres: complete necrosis of 
treated lesions. 
2.1.2 TACE with DcBead™ Microspheres: Clinical experiences 
Malagari presented the mid-term results of a single centre study from the 62 patients 
(cirrhotic with underlying hepatitis infection and documented unresectable HCC of 3-10 cm) 
Athenian Registry between December 2004 and March 2006. The aim of this study was to 
assess the safety and efficacy of doxorubicin loaded DC Bead in the treatment of 
unresectable HCC in cirrhotic patients. These patients were treated by selective or super-
selective embolisation using two different sizes of DC Bead: 100-300µm and/or 300-500µm 
loaded with 37.5mg/mL of doxorubicin. Follow-up lasted 32 months. This shows that 
chemoembolization using doxorubicin-loaded DC Beads is a safe and effective treatment of 
HCC as demonstrated by the low complication rate, increased tumor response, and 
sustained reduction of alpha-fetoprotein levels”. (Malagari et al, 2008) 
The PRECISION V study (Lammer et al., 2010) support these results. It consists of a 
randomized trial comparing conventional TACE (cTACE) with TACE using DC Bead™ 
Microspheres for the treatment of cirrhotic patients with HCC. 212 patients with Child-Pugh 
A/B cirrhosis and large and/or multinodular, unresectable, N0, M0 HCCs were 
randomized to receive cTACE with doxorubicin or TACE with DC Bead™ Microspheres 
loaded with doxorubicin. Randomization was stratified according to performance status 
(ECOG 0/1), Child-Pugh status (A/B), bilobar disease (yes/no), and prior curative 
treatment (yes/no). The primary endpoint was tumor response (EASL) at 6 months 
following independent, blinded review of MRI studies. The drug-eluting bead group 
showed higher rates of complete response, objective response, and disease control compared 
with the cTACE group (27% vs. 22%, 52% vs. 44%, and 63% vs. 52%, respectively). The 
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hypothesis of superiority was not found (one-sided P = 0.11). However, patients with Child-
Pugh B, ECOG 1, bilobar disease, and recurrent disease showed a significant increase in 
objective response (P = 0.038) compared to cTACE. DC Bead was associated with improved 
tolerability, with a significant  reduction in serious liver toxicity (P\0.001) and a significantly 
lower rate of doxorubicin-related side effects (P = 0.0001). This shows that TACE with DC 
Bead™ Microspheres and doxorubicin is safe and effective in the treatment of HCC and 
offers a benefit to patients with more advanced disease. 
2.2 TACE with HepaSphere Microspheres 
HepaSphere™ Microspheres are expandable microspheres approved for hepatic embolizations 
and chemoembolizations. They are Poly-sodium acrylate-vinyl alcohol Microspheres, 
developed in Japan by Dr Hori. They are available as 50 mg or 25 mg of dry powder, 
calibrated in 3 different dry sizes associated to different colours (yellow: 50-100 µm; blue: 100-
150 µm; red: 150-200 µm), sterilized by irradiation. Their diameter expands x4 and volume x64. 
They are negatively charged (anionic polymer), enabling strong interactions with positively 
charged drugs such as Doxorubicin reducing systemic toxicity. 
2.2.1 TACE with HepaSphere Microspheres: Preparation 
Prepare  in Biohazard Hood 
1. Using a 30 mL syringe and a 20G needle, reconstitute the 50 mg doxorubicin vial with 
20 mL preservative-free 0.9% sodium chloride. Do not use pure sterile water. 
2. Lift the cap from the HepaSphere™ vial to the vertical position taking care not to 
remove the cap or the metal retaining ring from the vial. 
3. Roll the HepaSphere™ vial several times to disperse microspheres. 
4. Using a new 30 mL syringe with a new 18 G needle, withdraw 20 mL (the intire 
contents) from the doxorubicin vial (50 mg) prepared in Step 1. 
5. Inject 10 mL of doxorubicin from Step 4 to the HepaSphere™ vial. Note: there may be a 
vacuum in the HepaSphere™ vial. 
6. Gently rotate and invert the HepaSphere™ vial back and forth 5 to 10 times so that the 
liquid contacts the grey stopper (do not shake vigorously). Let the vial stand for 10 
minutes; invert every few minutes to continue to mix the spheres with the doxorubicin. 
7. After the 10 minutes from Step 6, withdraw the entire contents of the HepaSphere™ 
vial into the 30 mL syringe containing the remaining doxorubicin (25 mg/10 mL) 
prepared in Step 4. (Do not attempt to extract every red colored sphere). Gently agitate 
the syringe back and forth to completely mix and disperse the contents.  
8. Remove the needle and cap the syringe. Note the time and wait 60 minutes to optimize 
the uptake of the doxorubicin into the spheres before administering. 
9. Do not begin this step until at least 60 minutes has elapsed from Step 8. Attach syringe 
to a 3-way stopcock. Allow the spheres to settle at the bottom. Purge 10 mL of the 
supernatant and discard. Add/replace with 10 mL of non-ionic contrast.  
10. Invert this syringe several times to disperse and mix the contents in the syringe until 
suspension is achieved. 
2.2.2 TACE with HepaSphere Microspheres: Clinical experiences 
We have reported  the early results of a multicentre Italian trial using HepaSphere™ 
Microspheres loaded with chemotherapeutic agents (doxorubicin or epirubicin) for TACE in 
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patients with unresectable hepatocellular carcinoma (December 2005 – March 2007; 50 
patients, 36 male – 14 female, mean age 68.4 years). The diameter of the treated lesions 
ranged from 20 to 100 mm (mean 42.5; maximum of 4 tumor nodules). Tumor response was 
evaluated by CTaccording to the World Health Organization criteria as modified by the 
European Association for the Study of Liver Diseases. Technical success was performed in 
all procedures without major complications. At 1-month CT follow-up, complete tumor 
response was observed in 24 of 50 (48%), partial response in 18 of 50 (36%), and stable 
disease in 8 of 50 (16%) patients without cases of disease progression. At 6-month follow-up 
(31/50 patients) complete tumor response was obtained in 16/31 (51.6%), partial response in 
8/31 (25.8%), and progressive disease in 7/31 (22.6%) patients. Within the initial 9-month 
follow-up, TACE with HepaSphere™ Microspheres was successfully repeated twice in 3 
patients, while 3 patients underwent the procedure 3 times. Our initial multicentre 
experience demonstrates that TACE using HepaSphere is feasible, is well tolerated, has a 
low complication rate, and is associated with promising tumor response. When complete 
tumor response in not achieved, additional treatments can be performed. 
Longer follow-up on larger series is mandatory to confirm these preliminary results. (Grosso 
et al., 2008) 
We compared our experience using HepaSphere™ microspheres (Biosphere Medical) 
loaded with Doxorubicin in patients with unresectable Hepatocellular Carcinoma with our 
precedent series of traditonal TACE: TACE with Lipiodol and Gelfoam (340 pts treated from 
December 1991 to April 1996) and TACE with Lipiodol and Embosphere (46 pts treated 
from February 2000 to November 2005). From December 2005 to December 2010, we treated 
111 patients (83 male, 28 female, mean age 71 years; 70% with a minimum follow-up of 6 
months) by selective TACE using HepaSphere™ loaded with Doxorubicin in 173 procedures. 
The diameter of  the lesions ranged from 25 to 176 mm (mean diameter: 61.5 mm; maximum: 
multifocal lesions). Technical success rate was 100%, with complete devascularization of the 
lesions at the end of all procedures. One month CT follow-up shows complete necrosis (90-
100%) of lesions in 39.9%, partial necrosis (50-89%) in  44.2%, progression disease (0-49%) in 
15.9%.  6 month follow-up shows complete necrosis in 32.4%, partial in 44.5%, progression 
disease in 23.1%. 39 patients underwent RFA (29 pre-TACE; 10 post-TACE); 12 were lost at 
follow-up, 5 died. Survival at 6 months was 93.8% in HepaSphere™, 91.3% in Embosphere, 
 
Fig. 5. Personal experience A.S.O. S. croce e Carle – Cuneo. Survival %. 
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77% in Gelfoam group; at 12 months it was 83.3% in HepaSphere™, 73.9% in Embosphere, 
59.1% in Gelfoam group; at 24 months was 55% in HepaSphere™, 41% in Embosphere, 19% 
in Gelfoam group (Figure 5). 
This comparison demonstrates that TACE using HepaSphere™ is feasible, with low 
complication rate and promising efficacy. 
Figures 5-6 demonstrate a case of HCC we treated with TACE with HepaSphere™ 
Microspheres and 1 months US-follow-up. 
 
Fig. 6. TACE with HepaSphere™. 
 
Fig. 7. 1-month US follow-up after TACE with HepaSphere™: complete necrosis of nodule 
of HCC we treated. 
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3. Conclusions 
TACE is the most successful treatment of intermediate HCC or HCC not suitable for 
resection and percutaneous ablation, improving the life quality an medium/long survival 
rates in patients with intermediate HCC. 
The results of TACE using Microspheres, compared with results of conventional TACE, are 
promising less side-effects, complications and especially seems to offer benefit to patients 
with advanced tumor. 
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